What are the recommended routes and dosages for tranexamic acid (Tranostat) injection and vitamin K?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Tranexamic Acid (Tranostat) and Vitamin K: Routes and Dosages

Tranexamic Acid (Tranostat)

For acute traumatic hemorrhage, administer tranexamic acid 1 g IV bolus over 10 minutes, followed by a second 1 g dose over 8 hours, given within 3 hours of injury. 1

Dosing by Clinical Context

Trauma/Major Hemorrhage:

  • Standard regimen: 1 g IV bolus over 10 minutes, then 1 g IV infusion over 8 hours 1
  • Must be given within 3 hours of injury - efficacy disappears after this window and may increase mortality if given beyond 3 hours 1
  • Alternative single-dose approach: 2 g IV bolus (supported by recent comparative data showing equivalent outcomes) 2, 3

Post-partum Hemorrhage:

  • 1 g IV (100 mg/mL) at 1 mL/min over 10 minutes
  • Second 1 g dose if bleeding continues after 30 minutes or restarts within 24 hours
  • Must be given within 3 hours of birth 4

Antifibrinolytic Therapy (Bleeding Complications):

  • 10-15 mg/kg IV over 20 minutes 5
  • Alternative: 1 g IV every 6 hours 6

Route Considerations

Intravenous is the preferred and standard route for acute hemorrhage management. While intramuscular and oral routes exist with bioavailabilities of 105% and 46% respectively 7, IV administration ensures rapid, predictable drug levels in emergency situations.


Vitamin K

For warfarin reversal with major bleeding or intracranial hemorrhage, administer vitamin K 10 mg IV slowly (not exceeding 1 mg/minute), combined with prothrombin complex concentrate. 5

Dosing by Clinical Context

Warfarin Reversal - Major Bleeding/Intracranial Hemorrhage:

  • 10 mg IV administered slowly over 10-15 minutes (maximum rate 1 mg/min) 5, 8
  • Must be combined with 4-factor prothrombin complex concentrate for immediate reversal 5
  • Redose with 10 mg IV if INR remains ≥1.4 at 24-48 hours 5

Warfarin Reversal - Non-Emergent (INR >10 without bleeding):

  • Oral vitamin K is acceptable 9

Pre-Operative Management (High Bleeding Risk):

  • 5 mg IV or oral if procedure planned >12 hours away 10
  • 5 mg IV combined with PCC if procedure must occur within 12 hours 10

Anticoagulant-Induced Prothrombin Deficiency (Non-Hemorrhagic):

  • 2.5-10 mg IV initially, up to 25 mg in severe cases 8
  • Rarely, 50 mg may be required 8

Newborn Hemorrhagic Disease:

  • Prophylaxis: 0.5-1 mg IM within 1 hour of birth 8
  • Treatment: 1 mg SC or IM 8

Route Selection

Intravenous route is preferred for urgent reversal as it produces more predictable and rapid INR reduction (4-6 hours) compared to oral (18-24 hours) 10, 11, 8. Subcutaneous administration is unpredictable and not recommended 11, 8.

Critical administration details:

  • Dilute in 25-50 mL normal saline
  • Infuse over 15-30 minutes, never exceeding 1 mg/minute 8
  • Protect from light during administration 8

Important Caveats

For Vitamin K:

  • Vitamin K alone does NOT provide immediate reversal - it requires hours to take effect and must be combined with PCC for life-threatening bleeding 5, 11
  • The 10 mg dose may prolong time to therapeutic INR when restarting warfarin; 5 mg is preferred for non-life-threatening situations 10

For Tranexamic Acid:

  • The 3-hour window is absolute - administration beyond this timeframe in trauma may be harmful 1, 4
  • Avoid in patients with known thromboembolic events during pregnancy (for post-partum use) 4
  • Single 2 g bolus regimens show equivalent outcomes to bolus-plus-infusion protocols, offering logistical advantages 2, 3

References

Research

The Use of Tranexamic Acid in Tactical Combat Casualty Care: TCCC Proposed Change 20-02.

Journal of special operations medicine : a peer reviewed journal for SOF medical professionals, 2020

Related Questions

What are the ATLS 11th edition updates for the xABCDE (massive external hemorrhage control, airway, breathing, circulation, disability, exposure) protocol, including recommended cervical collar use and tranexamic acid dosing for an emergency physician?
What is the appropriate tranexamic acid dosage (oral and intravenous) for a hemodynamically stable dengue patient with menorrhagia who can tolerate oral fluids?
For an 11-year-old child, is tranexamic acid 500 mg orally twice daily an excessive dose?
Is Tranexa (tranexamic acid) injection administered intravenously (IV) or intramuscularly (IM)?
What are the current recommendations for tranexamic acid (TXA) use, including timing, dosing, and contraindications, in trauma patients with significant hemorrhage?
What is the antihypertensive of choice for a 30-year-old female with polytrauma and subarachnoid hemorrhage who is intubated and has a femoral arterial blood pressure of 190/100 mm Hg?
How should a patient with a suspected snake bite, no first aid measures applied, and stable vital signs but feeling unwell be managed?
How should a pontine transient ischemic attack be evaluated and treated?
What is the differential diagnosis for acute erythematous, pustular lesions on the nasal tip and bridge in an elderly female receiving chemotherapy?
In a patient with a suspected venomous snake bite and a normal 20‑minute whole‑blood clotting test (WBCT), what is the appropriate management and observation plan?
What are the current and emerging treatment options, including research findings, for a patient with hypermobile Ehlers‑Danlos syndrome who has a history of spinal instability requiring surgical reattachment and recurrent hip dislocations requiring surgery?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.